These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29729523)

  • 1. High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells: Implications for cancer stem cell resistance.
    Ryoo IG; Choi BH; Ku SK; Kwak MK
    Redox Biol; 2018 Jul; 17():246-258. PubMed ID: 29729523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells.
    Ryoo IG; Choi BH; Kwak MK
    Oncotarget; 2015 Apr; 6(10):8167-84. PubMed ID: 25717032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PA-MSHA inhibits the growth of doxorubicin-resistant MCF-7/ADR human breast cancer cells by downregulating Nrf2/p62.
    Wei Y; Liu D; Jin X; Gao P; Wang Q; Zhang J; Zhang N
    Cancer Med; 2016 Dec; 5(12):3520-3531. PubMed ID: 27758045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling.
    Kim D; Choi BH; Ryoo IG; Kwak MK
    Cell Death Dis; 2018 Aug; 9(9):896. PubMed ID: 30166520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6/p62 associated Nrf2-antioxidant pathway activation.
    Noman ASM; Parag RR; Rashid MI; Islam S; Rahman MZ; Chowdhury AA; Sultana A; Jerin C; Siddiqua A; Rahman L; Nayeem J; Akther S; Baidya S; Shil RK; Rahman M; Shirin A; Mahmud R; Hossain SMI; Sumi SA; Chowdhury A; Basher SB; Hasan A; Bithy S; Aklima J; Chowdhury N; Hasan MN; Banu T; Chowdhury S; Hossain MM; Yeger H; Farhat WA; Islam SS
    Cell Death Dis; 2020 Aug; 11(8):663. PubMed ID: 32814771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
    Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
    J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of CD44
    Chekhun VF; Lukianova NY; Chekhun SV; Bezdieniezhnykh NO; Zadvorniy TV; Borikun TV; Polishchuk LZ; Klyusov OМ
    Exp Oncol; 2017 Sep; 39(3):203-211. PubMed ID: 28967645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
    Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.
    Boulbes DR; Chauhan GB; Jin Q; Bartholomeusz C; Esteva FJ
    Breast Cancer Res Treat; 2015 Jun; 151(3):501-13. PubMed ID: 25971596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
    Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
    Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
    Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
    BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of NRF2 with HIF-2α-induced cancer stem cell phenotypes in chronic hypoxic condition.
    Hallis SP; Kim SK; Lee JH; Kwak MK
    Redox Biol; 2023 Apr; 60():102632. PubMed ID: 36791645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells.
    Jiang P; Xu C; Chen L; Chen A; Wu X; Zhou M; Haq IU; Mariyam Z; Feng Q
    Mol Carcinog; 2018 Dec; 57(12):1835-1844. PubMed ID: 30182373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronic acid hydrogels with defined crosslink density for the efficient enrichment of breast cancer stem cells.
    Tan S; Yamashita A; Gao SJ; Kurisawa M
    Acta Biomater; 2019 Aug; 94():320-329. PubMed ID: 31125725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of Nrf2 Activity by Chestnut Leaf Extract Increases Chemosensitivity of Breast Cancer Stem Cells to Paclitaxel.
    Woo Y; Oh J; Kim JS
    Nutrients; 2017 Jul; 9(7):. PubMed ID: 28718813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMURF1 silencing diminishes a CD44-high cancer stem cell-like population in head and neck squamous cell carcinoma.
    Khammanivong A; Gopalakrishnan R; Dickerson EB
    Mol Cancer; 2014 Dec; 13():260. PubMed ID: 25471937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy?
    Wu T; Harder BG; Wong PK; Lang JE; Zhang DD
    Mol Carcinog; 2015 Nov; 54(11):1494-502. PubMed ID: 25154499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells.
    Weitzenfeld P; Meshel T; Ben-Baruch A
    Oncotarget; 2016 Dec; 7(49):81123-81143. PubMed ID: 27835603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nrf2/p62 signaling in apoptosis resistance and its role in cadmium-induced carcinogenesis.
    Son YO; Pratheeshkumar P; Roy RV; Hitron JA; Wang L; Zhang Z; Shi X
    J Biol Chem; 2014 Oct; 289(41):28660-75. PubMed ID: 25157103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.
    Olsson E; Honeth G; Bendahl PO; Saal LH; Gruvberger-Saal S; Ringnér M; Vallon-Christersson J; Jönsson G; Holm K; Lövgren K; Fernö M; Grabau D; Borg A; Hegardt C
    BMC Cancer; 2011 Sep; 11():418. PubMed ID: 21957977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.